(NANO) Nanobiotix S.A - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: PA (France) | Market Cap: 1.920m EUR | Total Return: 998.2% in 12m
Avg Turnover: 11.8M
Warnings
Negative Equity with losses - insolvent profile
Share dilution 22.2% YoY
Interest Coverage Ratio -3.7 is critical
Altman Z'' -10.20 < 1.0 - financial distress zone
Tailwinds
Leader, Tailwind, Confidence
Nanobiotix S.A. is a Paris-based clinical-stage biotechnology firm specializing in nanomedicine for oncology. The company’s core technology utilizes NBTXR3, a suspension of hafnium oxide nanoparticles designed to enhance the efficacy of radiotherapy across various solid tumors, including soft tissue sarcoma and head and neck cancers. This physical mechanism of action distinguishes the company from traditional biochemical drug developers, as the nanoparticles are engineered to maximize energy absorption within tumor cells without increasing the radiation dose to surrounding healthy tissue.
The business model relies on strategic international partnerships to scale clinical development and market access, evidenced by its licensing agreement with Lian Oncology for the Greater China and Southeast Asian markets. Biotechnology firms at this stage typically face high research and development expenses and significant regulatory hurdles before achieving commercial revenue. Investors may find it useful to examine ValueRay for deeper insights into the company’s clinical pipeline and valuation metrics. Nanobiotix continues to evaluate NBTXR3 in multiple global clinical trials to expand its therapeutic indications.
- Phase 3 head and neck cancer trial results dictate long-term valuation
- Janssen partnership milestone payments provide critical non-dilutive capital funding
- FDA and EMA regulatory approval timelines for NBTXR3 drive volatility
- Expansion of clinical pipeline into lung and pancreatic cancer applications
- Cash runway and burn rate influence potential for future equity dilution
| Net Income: -92.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.22 > 0.02 and ΔFCF/TA -39.70 > 1.0 |
| NWC/Revenue: 29.07% < 20% (prev 94.48%; Δ -65.40% < -1%) |
| CFO/TA -0.79 > 3% & CFO -53.5m > Net Income -92.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.4m) vs 12m ago 22.15% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 22.31% > 50% (prev 42.23%; Δ -19.92% > 0%) |
| Interest Coverage Ratio: -3.66 > 6 (EBITDA TTM -79.7m / Interest Expense TTM 22.3m) |
| A: 0.08 (Total Current Assets 62.8m - Total Current Liabilities 57.5m) / Total Assets 67.8m |
| B: -0.35 (Retained Earnings -24.0m / Total Assets 67.8m) |
| C: -1.01 (EBIT TTM -81.8m / Avg Total Assets 80.8m) |
| D: -2.62 (Book Value of Equity -398.7m / Total Liabilities 152.2m) |
| Altman-Z'' = -10.20 = D |
| DSRI: 1.78 (Receivables 7.68m/9.49m, Revenue 18.0m/39.7m) |
| GMI: 1.03 (GM 100.0% / 103.4%) |
| AQI: 2.00 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 0.45 (Revenue 18.0m / 39.7m) |
| TATA: -0.57 (NI -92.1m - CFO -53.5m) / TA 67.8m) |
| Beneish M = -2.74 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at EUR 33.52 with a total of 282,082 shares traded.
Over the past week, the price has changed by -16.80%,
over one month by +34.94%,
over three months by +71.17% and
over the past year by +998.19%.
Nanobiotix S.A has no consensus analysts rating.
P/E Forward = 73.5294
P/S = 58.9213
P/B = 61.9864
Revenue TTM = 18.0m EUR
EBIT TTM = -81.8m EUR
EBITDA TTM = -79.7m EUR
Long Term Debt = 89.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 4.31m EUR (from shortTermDebt, last quarter)
Debt = 98.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.10m
Net Debt = 87.6m EUR (calculated: Debt 98.4m - CCE 10.8m)
Enterprise Value = 2.01b EUR (1.92b + Debt 98.4m - CCE 10.8m)
Interest Coverage Ratio = -3.66 (Ebit TTM -81.8m / Interest Expense TTM 22.3m)
EV/FCF = -24.33x (Enterprise Value 2.01b / FCF TTM -82.5m)
FCF Yield = -4.11% (FCF TTM -82.5m / Enterprise Value 2.01b)
FCF Margin = -457.6% (FCF TTM -82.5m / Revenue TTM 18.0m)
Net Margin = -510.7% (Net Income TTM -92.1m / Revenue TTM 18.0m)
Gross Margin = unknown ((Revenue TTM 18.0m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 29.63 (Enterprise Value 2.01b / Total Assets 67.8m)
Interest Expense / Debt = 22.70% (Interest Expense 22.3m / Debt 98.4m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -61.4m (EBIT -81.8m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.98 (Total Current Assets 62.8m / Total Current Liabilities 64.1m)
Debt / Equity = -1.16 (negative equity) (Debt 98.4m / totalStockholderEquity, last quarter -84.5m)
Debt / EBITDA = -1.10 (negative EBITDA) (Net Debt 87.6m / EBITDA -79.7m)
Debt / FCF = -1.06 (negative FCF - burning cash) (Net Debt 87.6m / FCF TTM -82.5m)
Total Stockholder Equity = -60.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -113.9% (out of range, set to none)
RoE = 253.9% (negative equity) (Net Income TTM -92.1m / Total Stockholder Equity -36.3m)
RoCE = -154.8% (out of range, set to none) (EBIT -81.8m / Capital Employed (Equity -36.3m + L.T.Debt 89.1m))
RoIC = -456.8% (out of range, set to none) (NOPAT -61.4m / Invested Capital 13.4m)
WACC = 7.78% (E(1.92b)/V(2.02b) * Re(7.31%) + D(98.4m)/V(2.02b) * Rd(22.70%) * (1-Tc(0.25)))
Discount Rate = 7.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 15.01%
[DCF] Fair Price = unknown (Cash Flow -82.5m)
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -1.73 | # QB: -1
EPS current Year (2026-12-31): EPS=-0.09 | Chg30d=+87.31% | Revisions=+33% | GrowthEPS=+83.0% | GrowthRev=+52.6%
EPS next Year (2027-12-31): EPS=-0.36 | Chg30d=+17.24% | Revisions=+33% | GrowthEPS=-323.5% | GrowthRev=-2.4%
[Analyst] Revisions Ratio: +33%